All treatments
Treatment
Herceptin 600 mg solution for injection in vial clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A phase Ib study of Ipatasertib, an AKT inhibitor, in combination with Pertuzumab plus Trastuzumab in patients with PIK3CA-mutant, HER2-positive locally advanced or metastatic breast cancer.
This study looks at a new drug, ipatasertib, combined with standard treatments (Herceptin and Perjeta) for a specific type of advanced breast cancer. It aims to find the safest and most effective dose of ipatasertib for patients whose cancer has a particular genetic change (PIK3CA mutant) and a lot of HER2 protein.
For: Patients with PIK3CA-mutant · HER2-positive locally advanced or metastatic breast cancer · candidates to receive maintenance therapy with trastuzumab plus pertuzumab (HP) after first line treatment for metastatic disease with a taxane or vinorelbine plus HP.Spain - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase IIIB, Multinational, Multicenter, Randomized, Open-Label Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administrationin Participants with Early or Locally Advanced/ Inflammatory HER2-Positive Breast Cancer
This study looks at treating HER2-positive breast cancer. It compares giving a special medicine called Phesgo at home versus in the hospital to see which patients prefer. Researchers also check how well the treatment works and any side effects.
For: Early or Locally Advanced/ Inflammatory HER2-Positive Breast CancerSpain · Bulgaria · Croatia